74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
Bausch Health Cos Inc
Closed
SectorHealthcare
5.47 6.01
Overview
Share price change
24h
Min
5.12
Max
5.47
Income | 190M 98M |
|---|---|
Sales | 49M 2.6B |
EPS | 1.16 |
Profit margin | 3.83 |
Employees | 20,700 |
EBITDA | 206M 853M |
Recommendations | Neutral |
|---|---|
12 Months Forecast | +59.57% upside |
Next Earnings | 30 Apr 2025 |
|---|
Market Cap | -595M 1.7B |
|---|---|
Previous open | -0.54 |
Previous close | 5.47 |
Technical Score
By Trading Central
Confidence
Strong Bullish Evidence
Bausch Health Cos Inc Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Bausch Health Cos Inc Forecast
Price Target
By TipRanks
59.57% upside
12 Months Forecast
Average 8.25 USD 59.57%
High 12 USD
Low 5 USD
Based on 6 Wall Street analysts offering 12 month price targets forBausch Health Cos Inc - Dist in the last 3 months.
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Bausch Health Cos Inc
Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health. The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The Salix segment provides gastroenterology products in the United States. The International segment sells aesthetic medical devices, branded pharmaceuticals, generic pharmaceuticals, and OTC products internationally. The Solta Medical segment engages in the sale of aesthetic medical devices. The Diversified segment offers pharmaceutical products in the areas of neurology and certain other therapeutic classes; generic products; ortho dermatologic; and dentistry products in the United States. The Bausch + Lomb segment offers products in the areas of vision care, surgical, and ophthalmic pharmaceuticals products. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.
